PMID- 10550550
OWN - NLM
STAT- MEDLINE
DCOM- 19991119
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 48
IP  - 8
DP  - 1999 Nov
TI  - Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 x 
      anti-c-ErbB-2 bispecific antibody.
PG  - 456-62
AB  - T helper type1 (Th1) or type2 (Th2) cells were induced from naive Th cells 
      obtained from ovalbumin-specific T cell receptor (TCR) transgenic mice. Th1 cells 
      producing interferon gamma (IFNgamma) exhibited stronger antigen-specific 
      cytotoxicity against ovalbumin-(323-339)-peptide-pulsed A20 tumor cells than did 
      Th2 cells. To develop a general method for applying antigen-nonspecific Th1 cells 
      to tumor immunotherapy, we examined the targeting of Th1 cells to tumor cells 
      using a bispecific antibody (bsAb) consisting of anti-(mouse CD3) mAb and 
      anti-(human c-ErbB-2) mAb. When ovalbumin-specific Th1 or Th2 cells were 
      cocultured with c-erbB-2-positive transfectants (CMS7HE), neither type of cell 
      showed significant cytotoxicity or cytokine production in response to tumor 
      cells. However, addition of bsAb resulted in the triggering of both Th1 and Th2 
      cells. Th1 cells showed higher levels of bsAb-dependent cytotoxicity against 
      CMS7HE tumor cells than did Th2 cells. The targeting of Th1 cells to CMS7HE tumor 
      cells by bsAb also triggered the production of cytokines such as IFNgamma, 
      interleukin-2 and tumor necrosis factor alpha (TNFalpha). The released TNFalpha 
      was demonstrated to be a critical cytolytic factor in bsAb-mediated cytotoxicity 
      by Th1 cells. Finally, Th1 cells were demonstrated to show antitumor activity in 
      vivo against human c-erbB-2-positive tumor cells implanted in nude mice. These 
      results suggest that Th1 cells are useful effector cells for the application to 
      adoptive tumor immunotherapy in conjunction with bsAb.
FAU - Ohmi, Y
AU  - Ohmi Y
AD  - Section of Genetic Engineering, Research Center for Genetic Engineering and Cell 
      Transplantation, Tokai University School of Medicine, Bohseidai, Isehara 
      259-1193, Japan.
FAU - Shiku, H
AU  - Shiku H
FAU - Nishimura, T
AU  - Nishimura T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (CD3 Complex)
RN  - 0 (Cytokines)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 187348-17-0 (Interleukin-12)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - Antibodies, Bispecific/*immunology
MH  - CD3 Complex/*immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Cytokines/biosynthesis
MH  - Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Interleukin-12/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Mice, Transgenic
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/therapy
MH  - Receptor, ErbB-2/*immunology/metabolism
MH  - Receptors, Antigen, T-Cell/genetics
MH  - Th1 Cells/*immunology
MH  - Th2 Cells/immunology
MH  - Tumor Cells, Cultured
PMC - PMC11037147
EDAT- 1999/11/07 00:00
MHDA- 1999/11/07 00:01
PMCR- 1999/10/01
CRDT- 1999/11/07 00:00
PHST- 1999/11/07 00:00 [pubmed]
PHST- 1999/11/07 00:01 [medline]
PHST- 1999/11/07 00:00 [entrez]
PHST- 1999/10/01 00:00 [pmc-release]
AID - 90480456.262 [pii]
AID - 10.1007/s002620050622 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 1999 Nov;48(8):456-62. doi: 10.1007/s002620050622.